Document is current
Any future updates will be listed below
-
Authors
Gorgogietas, Vyron
Weiss, Amélie
Cousin, Loïc
Hoffmann, David
Schmitt, Karen
Ogier, Arnaud
Barbuti, Peter A.
Santos, Bruno F. R.
Boussaad, Ibrahim
Wittich, Annika
Zaliani, Andrea
Pless, Ole
Krüger, Rejko
Sommer, Peter
Wilbertz, Johannes H.
-
Funding
Funding for this research was provided by:
European Joint Program on Rare Diseases (01GM2002B)
Fonds National de la Recherche Luxembourg (“MOTASYN” (No.12719684))
Secrétariat général pour l’investissement (Programme d’investissements d’avenir (PIA))
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 4 August 2025
First Online: 12 August 2025
Declarations
:
: A.We., L.C., D.H., K.S., A.O., P.S., and J.H.W. are or were employed by Ksilink. R.K. is receiving or has received research grants from the European Institute of Innovation and Technology (EIT Health), the Innovative Medicines Initiative (IMI) of the European Union and the European pharmaceutical industry, as well as personal speaker’s honoraria and/or travel grants from Abbvie, Zambon and Medtronic; R.K. participated as PI or site-PI for industry sponsored clinical trials without receiving honoraria. All other authors declare no conflict of interest.
